NasdaqGM:SMMTBiotechs
Should Summit Therapeutics’ Canceled US$500 Million Equity Offering Reshape SMMT Investors’ View on Financing Strategy?
Earlier this month, Summit Therapeutics filed and then withdrew a US$500.00 million follow-on equity offering of 35,435,861 common shares at an indicated US$14.11 price range after announcing positive Phase II/III data for its lead cancer drug ivonescimab in non-small cell lung and metastatic colorectal cancers.
The combination of encouraging ivonescimab trial outcomes with a halted equity raise highlights how Summit is balancing funding needs against market conditions as it advances a...